Tim C P Somervaille
Overview
Explore the profile of Tim C P Somervaille including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
74
Citations
2834
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gurashi K, Wang Y, Amaral F, Spence K, Cant R, Yao C, et al.
Cell Rep Med
. 2025 Feb;
6(2):101933.
PMID: 39892394
Approximately 30% of patients with chronic myelomonocytic leukemia (CMML) undergo transformation to a chemo-refractory blastic phase (BP-CMML). Seeking novel therapeutic approaches, we profiled blast transcriptomes from 42 BP-CMMLs, observing extensive...
2.
Addinsell H, Cant R, Hull N, Wang Y, Somervaille T, Wiseman D, et al.
Leukemia
. 2025 Jan;
39(3):770-774.
PMID: 39815051
No abstract available.
3.
Ramachandran R, Ibragimova S, Woods L, AlHouqani T, Gomez R, Simeoni F, et al.
iScience
. 2024 Aug;
27(8):110500.
PMID: 39171293
Triple-negative breast cancer (TNBC) is characterized by lack of the estrogen (ER) receptor, progesterone receptor (PR), and human epidermal growth factor receptor-2 (HER2), and standard receptor-targeted therapies are ineffective. FOXC1,...
4.
Salamero O, Molero A, Perez-Simon J, Arnan M, Coll R, Garcia-Avila S, et al.
Lancet Haematol
. 2024 Jun;
11(7):e487-e498.
PMID: 38824932
Background: Iadademstat is a potent, selective, oral inhibitor of both the enzymatic and scaffolding activities of the transcriptional repressor lysine-specific demethylase 1 (LSD1; also known as KDM1A) that showed promising...
5.
Gupta V, Oh S, Devos T, Dubruille V, Catalano J, Somervaille T, et al.
Leuk Lymphoma
. 2024 Mar;
65(7):965-977.
PMID: 38501751
A key hallmark of myelofibrosis is anemia, which ranges from mild to severe based on hemoglobin levels. To more clearly define outcomes with the Janus kinase (JAK) 1/JAK2/activin A receptor...
6.
McLornan D, Psaila B, Ewing J, Innes A, Arami S, Brady J, et al.
Br J Haematol
. 2023 Dec;
204(1):136-150.
PMID: 38037886
No abstract available.
7.
Nicosia L, Spencer G, Brooks N, Amaral F, Basma N, Chadwick J, et al.
Cancer Cell
. 2023 Nov;
41(12):2136-2153.e13.
PMID: 37995682
CCS1477 (inobrodib) is a potent, selective EP300/CBP bromodomain inhibitor which induces cell-cycle arrest and differentiation in hematologic malignancy model systems. In myeloid leukemia cells, it promotes rapid eviction of EP300/CBP...
8.
Rampotas A, Carter-Brzezinski L, Somervaille T, Forryan J, Panitsas F, Harrison C, et al.
Blood
. 2023 Nov;
143(2):178-182.
PMID: 37963262
Nonmelanoma skin cancers (NMSCs) in ruxolitinib-treated patients with myeloproliferative neoplasms behave aggressively, with adverse features and high recurrence. In our cohort, mortality from metastatic NMSC exceeded that from myelofibrosis. Vigilant...
9.
McLornan D, Godfrey A, Green A, Frewin R, Arami S, Brady J, et al.
Br J Haematol
. 2023 Nov;
204(1):127-135.
PMID: 37932932
No abstract available.
10.
Ginn L, Maltas J, Baker M, Chaturvedi A, Wilson L, Guilbert R, et al.
Proc Natl Acad Sci U S A
. 2023 Sep;
120(40):e2300489120.
PMID: 37748077
Lung cancer is the leading cause of cancer deaths. Its high mortality is associated with high metastatic potential. Here, we show that the RAC1-selective guanine nucleotide exchange factor T cell...